Merit Medical Systems (MMSI) has filed a US$270.135 million shelf registration for up to 2,700,000 common shares tied to an ESOP related offering, shortly after raising full year 2026 revenue guidance.

Despite stronger first quarter results and raised 2026 revenue guidance, Merit Medical Systems’ share price has come under pressure, with the stock down 12.47% on a 30 day share price return basis and the 1 year total shareholder return declining 37.91%. This suggests that recent equity issuance plans and mixed insider activity are weighing on sentiment.

If this ESOP linked issuance has you thinking about where else capital could work hard in healthcare, it may be worth scanning for other medical technology and healthcare AI opportunities using the Simply Wall St screener for 32 healthcare AI stocks.

With the stock down sharply over the past year, trading at a reported 36% discount to intrinsic value and almost 48% below analyst targets, investors may wonder: is this genuine mispricing, or is the market already factoring in future growth?

Most Popular Narrative: 37.6% Undervalued

At a last close of $61.36 versus a narrative fair value of $98.36, the current setup reflects a wide gap that hinges on execution and margins.

Ongoing investments in operational efficiency, manufacturing automation, and product portfolio expansion through innovation and strategic M&A are driving improved gross and operating margins (evidenced by record 21% non-GAAP operating margin), supporting higher cash flow and net earnings. Regulatory support for medical device innovation, including NTAP approval and ongoing CMS engagement for WRAPSODY CIE, alongside successful cross-selling of new product lines into existing channels, establish strong long-term catalysts for above-peer revenue growth and margin expansion once reimbursement uncertainties resolve.

Curious what kind of revenue glide path, margin lift, and future earnings multiple need to line up to support that gap to fair value? The narrative sets out a tight sequence of volume growth, profitability gains, and a richer valuation profile that all have to land together. If you want to see exactly which financial levers carry the most weight in that $98.36 figure, the full story is worth a look.

Result: Fair Value of $98.36 (UNDERVALUED)

However, this gap to fair value sits alongside real pressure points, including WRAPSODY CIE reimbursement delays and rising operating costs that could weigh on the margin story.

Another Lens On Valuation: Earnings Multiple Check

The analyst narrative and SWS fair value suggest Merit Medical Systems is 35.8% below fair value, yet the current P/E of 26.3x sits above both the US Medical Equipment industry at 24.2x and the fair ratio of 21.7x. That mix of “cheap” on cash flows and “expensive” on earnings raises a simple question for you: what if the market drifts closer to that lower fair ratio instead?

Next Steps

If the mix of pressure points and potential rewards feels finely balanced, it is worth looking through the underlying metrics yourself and weighing the trade offs. To see which positives our model highlights for this stock, review its 3 key rewards

Looking for more investment ideas?

If you stop with just one stock, you risk missing other opportunities that might fit your goals even better, so give yourself options and compare a few.

• Target stability and income potential by scanning companies described as 12 dividend fortresses to see which yields and payout histories line up with your needs.
• Hunt for quality at a sensible price by reviewing the 50 high quality undervalued stocks and seeing which businesses match your return and risk expectations.
• Prioritise financial resilience by focusing on the solid balance sheet and fundamentals stocks screener (45 results) so you are not caught off guard by fragile balance sheets.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.